Format
Items per page
Sort by

Send to:

Choose Destination

Results: 17

References for PMC Articles for PubMed (Select 23593084)

1.

Implications of bone-only metastases in breast cancer: favorable preference with excellent outcomes of hormone receptor positive breast cancer.

Lee SJ, Park S, Ahn HK, Yi JH, Cho EY, Sun JM, Lee JE, Nam SJ, Yang JH, Park YH, Ahn JS, Im YH.

Cancer Res Treat. 2011 Jun;43(2):89-95. doi: 10.4143/crt.2011.43.2.89. Epub 2011 Jun 30.

2.

Exemestane in postmenopausal women with early or advanced breast cancer: a review.

Bertelli G, Gangadhara S.

Expert Opin Pharmacother. 2010 Aug;11(11):1933-42. doi: 10.1517/14656566.2010.495945. Review.

PMID:
20569090
3.

Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.

Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO.

J Natl Cancer Inst. 2009 May 20;101(10):736-50. doi: 10.1093/jnci/djp082. Epub 2009 May 12.

4.

Breast cancer. Clinical practice guidelines in oncology.

Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Jahanzeb M, Kiel K, Ljung BM, Marcom PK, Mayer IA, McCormick B, Nabell LM, Pierce LJ, Reed EC, Smith ML, Somlo G, Theriault RL, Topham NS, Ward JH, Winer EP, Wolff AC; NCCN Breast Cancer Clinical Practice Guidelines Panel.

J Natl Compr Canc Netw. 2009 Feb;7(2):122-92. Review. No abstract available.

PMID:
19200416
5.

Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation?

Lønning PE.

Eur J Cancer. 2009 Mar;45(4):527-35. doi: 10.1016/j.ejca.2008.10.019. Epub 2008 Dec 4. Review.

PMID:
19062270
6.

Activity of fulvestrant versus exemestane in advanced breast cancer patients with or without visceral metastases: data from the EFECT trial.

Mauriac L, Romieu G, Bines J.

Breast Cancer Res Treat. 2009 Sep;117(1):69-75. doi: 10.1007/s10549-008-0141-z. Epub 2008 Nov 23.

PMID:
19030986
7.

Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group.

Paridaens RJ, Dirix LY, Beex LV, Nooij M, Cameron DA, Cufer T, Piccart MJ, Bogaerts J, Therasse P.

J Clin Oncol. 2008 Oct 20;26(30):4883-90. doi: 10.1200/JCO.2007.14.4659. Epub 2008 Sep 15.

8.

Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.

Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M, Fein L, Romieu G, Buzdar A, Robertson JF, Brufsky A, Possinger K, Rennie P, Sapunar F, Lowe E, Piccart M.

J Clin Oncol. 2008 Apr 1;26(10):1664-70. doi: 10.1200/JCO.2007.13.5822. Epub 2008 Mar 3.

10.

Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients.

Carlini P, Michelotti A, Ferretti G, Ricci S, Giannarelli D, Pellegrini M, Cresti N, Di Cosimo S, Bria E, Papaldo P, Fabi A, Ruggeri EM, Milella M, Alimonti A, Salesi N, Cognetti F.

Cancer Invest. 2007 Mar;25(2):102-5.

PMID:
17453821
11.

Exemestane after non-steroidal aromatase inhibitors for post-menopausal women with advanced breast cancer.

Chin YS, Beresford MJ, Ravichandran D, Makris A.

Breast. 2007 Aug;16(4):436-9. Epub 2007 Apr 6.

PMID:
17418575
12.

HER2 testing in breast cancer: NCCN Task Force report and recommendations.

Carlson RW, Moench SJ, Hammond ME, Perez EA, Burstein HJ, Allred DC, Vogel CL, Goldstein LJ, Somlo G, Gradishar WJ, Hudis CA, Jahanzeb M, Stark A, Wolff AC, Press MF, Winer EP, Paik S, Ljung BM; NCCN HER2 Testing in Breast Cancer Task Force.

J Natl Compr Canc Netw. 2006 Jul;4 Suppl 3:S1-22; quiz S23-4. Review.

PMID:
16813731
13.

Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer.

Bertelli G, Garrone O, Merlano M, Occelli M, Bertolotti L, Castiglione F, Pepi F, Fusco O, Del Mastro L, Leonard RC.

Oncology. 2005;69(6):471-7. Epub 2006 Jan 12.

PMID:
16410685
14.

Exemestane in metastatic breast cancer: effective therapy after third-generation non-steroidal aromatase inhibitor failure.

Steele N, Zekri J, Coleman R, Leonard R, Dunn K, Bowman A, Manifold I, Kunkler I, Purohit O, Cameron D.

Breast. 2006 Jun;15(3):430-6. Epub 2005 Oct 19.

PMID:
16236514
15.

Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis.

Solomayer EF, Diel IJ, Meyberg GC, Gollan C, Bastert G.

Breast Cancer Res Treat. 2000 Feb;59(3):271-8.

PMID:
10832597
16.

Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial.

Lønning PE, Bajetta E, Murray R, Tubiana-Hulin M, Eisenberg PD, Mickiewicz E, Celio L, Pitt P, Mita M, Aaronson NK, Fowst C, Arkhipov A, di Salle E, Polli A, Massimini G.

J Clin Oncol. 2000 Jun;18(11):2234-44.

PMID:
10829043
17.

Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.

Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N, Dugardyn JL, Nasurdi C, Mennel RG, Cervek J, Fowst C, Polli A, di Salle E, Arkhipov A, Piscitelli G, Miller LL, Massimini G.

J Clin Oncol. 2000 Apr;18(7):1399-411.

PMID:
10735887
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk